Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Current Press Releases

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. at the Piper Jaffray 28th Annual Healthcare Conference  (Replay)
11/29/16 at 11:00 a.m. ET
Pacira Pharmaceuticals, Inc. at the Piper Jaffray 28th Annual Healthcare Conference
Tuesday, November 29, 2016 11:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
Recent Press Releases | Archived Press Releases
DateTitle 
11/29/16Pacira Pharmaceuticals and GeneAlign Announce Partnership to Develop Low-Opioid Pain Management Protocols for Postsurgical Patients at High Risk of Addiction
Collaboration will leverage genetic testing to identify patients predisposed to developing addiction following opioid exposure PARSIPPANY, N.J., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced a joint endeavor with GeneAlign, a therapeutic management and solutions company working to revolutionize personalized medicine through a patient-specific opioid risk assessment program that includes behavioral surveys, educational tools and genetic testing. U... 
Printer Friendly Version
11/22/16American College of Surgeons Launches Education Program on Opioids and Surgery: Use, Abuse, and Alternatives
Pacira grant will allow for the development and distribution of resources to educate patients and surgeons on opioid use in surgical care CHICAGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- The American College of Surgeons (ACS) today announced a new multifaceted initiative to improve the knowledge and management of pain in surgical patients with a focus on opioid risk and non-opioid alternatives. With an educational grant from Pacira Pharmaceuticals, Inc. (Pacira), ACS will develop Opioids and Sur... 
Printer Friendly Version
11/11/16Pacira Pharmaceuticals Unveils Virtual Reality Training Simulation to Enhance Administration Technique Education for EXPAREL® in Total Knee Replacement Surgery
3D Mobile Simulation Will Also Debut in Pacira Booth #907 at AAHKS 2016 PARSIPPANY, N.J., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today introduced a revolutionary new virtual reality simulation intended to provide clinicians with an immersive, hands-on training experience to reinforce the recommended technique for administering EXPAREL (bupivacaine liposome injectable suspension) in total knee arthroplasty (TKA) based on the infiltration protocol developed... 
Printer Friendly Version
11/10/16Correction: Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (9:00 a.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/10/16Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in November
PARSIPPANY, N.J., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November: Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (7:00 p.m. ET) in London on Thursday, November 17, 2016. 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016. Live audio webcasts of ... 
Printer Friendly Version
11/02/16Pacira Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results
-- Total Net Revenues Up 10% Year-Over-Year -- -- EXPAREL® Net Product Sales Up 9% Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2016. “EXPAREL revenues continued to grow year-... 
Printer Friendly Version
10/20/16Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
Company Appoints Thomas Sluby as Vice President, Sales and Matthew Lehmann as Vice President, Marketing PARSIPPANY, N.J., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Sluby has been named Vice President, Sales and Matthew Lehmann has been appointed Vice President, Marketing – Emerging Therapies; both individuals will repor... 
Printer Friendly Version
10/17/16Pacira Pharmaceuticals Announces Timing for Third Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2016 will be released before the market opens on Wednesday, November 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Wednesday, November 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (d... 
Printer Friendly Version
09/21/16Pacira Pharmaceuticals Announces Official Launch of EXPAREL to the Oral Surgeon Community to Treat Pain Following Oral and Maxillofacial Procedures
New research presented at AAOMS 2016 shows EXPAREL is safe and effective for pain relief following removal of wisdom teeth PARSIPPANY, N.J., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced new data regarding the benefit of EXPAREL® (bupivacaine liposome injectable suspension) for patients undergoing third molar (wisdom teeth) extraction, marking the official launch of the product to the oral surgeon community. EXPAREL is a local analgesic that pro... 
Printer Friendly Version
09/01/16Pacira Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
PARSIPPANY, N.J., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Morgan Stanley Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” sec... 
Printer Friendly Version
08/09/16Pacira Pharmaceuticals, Inc. to Present at the 2016 Wedbush PacGrow Healthcare Conference
PARSIPPANY, N.J., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the 2016 Wedbush PacGrow Healthcare Conference at 10:20 a.m. ET on Tuesday, August 16, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section... 
Printer Friendly Version
08/04/16Pacira Pharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results
-- Total Net Revenues Up 18% Year-Over-Year -- -- EXPAREL® Net Product Sales Up 15% Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the second quarter ended June 30, 2016. “The second quarter marked another period of... 
Printer Friendly Version
08/01/16New Research: Opioid Addiction and Dependence After Surgery is Significantly Higher than Previously Known
Vast Majority of Surgeons Feel Pressure to Prescribe More Opioids than Patients Need Gabrielle Reece ... 
Printer Friendly Version
07/15/16Pacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., July 15, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s second quarter ended June 30, 2016 will be released before the market opens on Thursday, August 4, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, August 4, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) o... 
Printer Friendly Version
05/31/16Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2016 Healthcare Conference
PARSIPPANY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, Chief Executive Officer and Chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2016 Healthcare Conference at 9 a.m. ET on Tuesday, June 7, 2016, in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the compan... 
Printer Friendly Version
05/03/16Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PARSIPPANY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, President of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference at 8:40 a.m. PT (11:40 a.m. ET) on Tuesday, May 10, 2016, in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
05/02/16Pacira Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results
-- Total Net Revenues Up 12 Percent Year-Over-Year -- -- EXPAREL® Net Revenues Up 14 Percent Year-Over-Year -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., May 02, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2016. “With immense leverage across our or... 
Printer Friendly Version
04/19/16Pacira Pharmaceuticals Appoints Charles A. Reinhart III as Chief Financial Officer
PARSIPPANY, N.J., April 19, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Charles A. Reinhart III to the position of Chief Financial Officer. Mr. Reinhart will be responsible for overseeing all financial and capital market activities at Pacira, including accounting, financial reporting, financial planning and analysis and investor relations. In this position, he will succeed former Chief Financial Officer Jim Scibetta, who is currently P... 
Printer Friendly Version
04/14/16Pacira Pharmaceuticals Announces Timing for First Quarter 2016 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., April 14, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s first quarter ended March 31, 2016 will be released before the market opens on Monday, May 2, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Monday, May 2, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-5... 
Printer Friendly Version
04/05/16Pacira Pharmaceuticals Appoints Robert Weiland as Chief Commercial Officer
PARSIPPANY, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Robert Weiland to the position of Chief Commercial Officer. Mr. Weiland will be responsible for oversight of the commercial activities for EXPAREL® (bupivacaine liposome injectable suspension), which include marketing, sales, national accounts, training and commercial operations and analytics. Mr. Weiland will report to Jim Scibetta, President and Chief Financial O... 
Printer Friendly Version
03/08/16Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
PARSIPPANY, N.J., March 08, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference at 9 a.m. ET on Tuesday, March 15, 2016, in Miami. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the co... 
Printer Friendly Version
03/01/16New Analysis Shows Use of EXPAREL Reduces Length of Hospital Stay and Improves Discharge Status Compared to Standard Analgesic Modality in Total Knee Arthroplasty
Data Presented at the Annual Meeting of the American Academy of Orthopaedic Surgeons PARSIPPANY, N.J., March 01, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of new data showing that EXPAREL® (bupivacaine liposome injectable suspension) infiltration compared to a standard analgesic regimen in patients undergoing total knee arthroplasty (TKA) significantly decreased the length of hospital stay and increased the likelihood that a patient would be d... 
Printer Friendly Version
02/25/16Pacira Pharmaceuticals, Inc. Reports 2015 Financial Results
-- 2015 Total Net Revenues Up 26 Percent Over 2014 -- -- 2015 EXPAREL® Net Revenues Up 27 Percent Over 2014 -- -- Per-Protocol Analysis of Oral Surgery Data Demonstrates Statistical Significance; Supports Launch Activities in Late Third Quarter 2016 --   -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain i... 
Printer Friendly Version
02/11/16Pacira Pharmaceuticals Announces Timing for 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2015 will be released before the market opens on Thursday, February 25, 2016. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, February 25, 2016, at 9 a.m. ET. The call can be accessed by dialing 1-877-84... 
Printer Friendly Version
01/07/16Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
PARSIPPANY, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015.  These estimates, which are unaudited, are based on management’s preliminary financial analysis. “We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the yea... 
Printer Friendly Version
12/28/15Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 4 p.m. PT (7 p.m. ET) on Monday, January 11, 2016, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors &... 
Printer Friendly Version
12/15/15Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call Today at 8:30 am EST – PARSIPPANY, N.J., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has achieved an amicable resolution with the United States in its lawsuit filed on September 8, 2015, Pacira Pharmaceuticals, Inc. et al v. United States Food &am... 
Printer Friendly Version
Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com